Overview A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults Status: Completed Trial end date: 2011-12-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 14 days of treatment with PF-05180999 in healthy subjects. Phase: Phase 1 Details Lead Sponsor: Pfizer